- Home
- LYT vs CYCC Comparison
LYT vs CYCC Comparison
Compare LYT & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYT
- CYCC
- Stock Information
- Founded
- LYT 2020
- CYCC 1992
- Country
- LYT India
- CYCC United States
- Employees
- LYT N/A
- CYCC N/A
- Industry
- LYT EDP Services
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- LYT Technology
- CYCC Health Care
- Exchange
- LYT Nasdaq
- CYCC Nasdaq
- Market Cap
- LYT 2.3M
- CYCC 2.3M
- IPO Year
- LYT 2022
- CYCC N/A
- Fundamental
- Price
- LYT $1.07
- CYCC $0.34
- Analyst Decision
- LYT
- CYCC Buy
- Analyst Count
- LYT 0
- CYCC 2
- Target Price
- LYT N/A
- CYCC $11.00
- AVG Volume (30 Days)
- LYT 88.8K
- CYCC 431.0K
- Earning Date
- LYT 08-15-2024
- CYCC 11-12-2024
- Dividend Yield
- LYT N/A
- CYCC N/A
- EPS Growth
- LYT N/A
- CYCC N/A
- EPS
- LYT 0.30
- CYCC N/A
- Revenue
- LYT $21,363,775.00
- CYCC $74,000.00
- Revenue This Year
- LYT N/A
- CYCC N/A
- Revenue Next Year
- LYT N/A
- CYCC $88.68
- P/E Ratio
- LYT $4.00
- CYCC N/A
- Revenue Growth
- LYT 12.39
- CYCC N/A
- 52 Week Low
- LYT $1.02
- CYCC $0.32
- 52 Week High
- LYT $18.62
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- LYT 29.10
- CYCC 37.88
- Support Level
- LYT $1.04
- CYCC $0.33
- Resistance Level
- LYT $1.24
- CYCC $0.42
- Average True Range (ATR)
- LYT 0.12
- CYCC 0.04
- MACD
- LYT -0.03
- CYCC 0.01
- Stochastic Oscillator
- LYT 13.97
- CYCC 8.21
About LYT Lytus Technologies Holdings PTV. Ltd.
Lytus Technologies Holdings Pvt Ltd is a platform services company providing content streaming/telecasting services to users located all across India. Its scope of business also covers telemedicine services with local assistance through local Health Centers. Through its platform, the customers are well connected via customer premises equipment (CPE) devices/set-top boxes (STBs) and have access to multi-dimensional services including telemedicine service.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.